invest financial


China’s Huishan Dairy Co. (HKG: 6863) took a note from Sears’ handbook on insider buying – and failed miserably.

Shares of the Chinese stock sank by a record 85% in Hong Kong on Friday in one of the city’s biggest sell-offs, wiping billions from its market value. Before the crash, the firm had a market capitalization of $4.85 billion; now it’s worth only $750 million.

The stock’s collapse is a huge blow to the Red Dragon, as Huishan is the country’s largest dairy farmer and has over 78 farms spread across Greater China. Before Friday’s plunge, Huishan had been one of the most stable stocks in Hong Kong.

The stock stopped trading at HK$0.42, or US$0.05, after which Huishan shares were suspended by Hong Kong’s exchange.

invest financial: Scana Corporation(SCG)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Monday, utilities shares were relative laggards, down on the day by about 0.43 percent. Meanwhile, top losers in the sector included SCANA Corporation (NYSE: SCG), down 2 percent, and FirstEnergy Corp. (NYSE: FE), down 2 percent.

  • [By Lisa Levin]

    In trading on Friday, utilities shares were relative laggards, down on the day by about 0.32 percent. Meanwhile, top losers in the sector included Genie Energy Ltd (NYSE: GNE), down 3 percent, and SCANA Corporation (NYSE: SCG), down 3 percent.

  • [By Lisa Levin]

    In trading on Tuesday, utilities shares rose by just 0.1 percent. Meanwhile, top losers in the sector included Atlantic Power Corp (NYSE: AT), down 2 percent, and SCANA Corporation (NYSE: SCG) down 1 percent.

invest financial: Ebix, Inc.(EBIX)

Advisors’ Opinion:

  • [By Peter Graham]

    Small cap insurance software stock Ebix Inc (NASDAQ: EBIX) reported Q1 2017 earnings before the market opened this morning. Q1 revenue rose 11% to $79.1 million and decreased 1% over Q4 2016 revenue of $80.0 million. The year over year revenue improvement reflected growth in the Companys Exchange, Risk Compliance, and Broker Solution channels. On a constant currency basis, Q1 revenue increased 10% to $78.5 millionwith theExchange channel continued to bethe Companyslargest -accounting for 67% of Q1 2017 revenues. Q1 2017 net income rose 19% to $26.4 million with the improvement principally reflected the benefit of higher revenues and operating income as compared to the same period last year.

invest financial: Sotheby's(BID)


Advisors’ Opinion:

  • [By Travis Hoium]

    Shares of auction house Sotheby’s (NYSE:BID) jumped as much as 14.7% in trading Monday after the company released fourth-quarter results. And shares kept steaming, trading 13.6% higher as of 12:30 p.m. EST.

  • [By Marshall Hargrave]

    Now Loeb's looking to put that capital to work in other markets, with the art market being a perfect candidate. Loeb and his Third Point hedge fund have started their latest activist campaign with leading auction house Sotheby's (NYSE: BID). Loeb joins fellow activist investor Marcato Capital in the stock.

  • [By Lisa Levin]

    Sothebys (NYSE: BID) reported better-than-expected results for its fourth quarter on Monday.

    Sothebys posted quarterly adjusted earnings of $1.35 per share on revenue of $308.69 million. Analysts were expecting earnings of $1.17 per share on revenue of $277.28 million.

invest financial: Sapiens International Corporation N.V.(SPNS)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
    Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
    Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
    Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
    Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
    Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
    Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
    Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
    Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
    Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
    BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
    Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
    Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than

invest financial: First Trust NASDAQ-100- Technology Index Fund(QTEC)


Advisors’ Opinion:

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Amazon.com, Inc. (NASDAQ: AMZN): Free Stock Analysis Report
     
    Netflix, Inc. (NASDAQ: NFLX): Free Stock Analysis Report
     
    Facebook, Inc. (NASDAQ: FB): Free Stock Analysis Report
     
    Alphabet Inc. (NASDAQ: GOOGL): Free Stock Analysis Report
     
    Apple Inc. (NASDAQ: AAPL): Free Stock Analysis Report
     
    SPDR-TECH SELS (ETF:XLK): ETF Research Reports
     
    NASDAQ-100 SHRS (NASDAQ: QQQ): ETF Research Reports
     
    SPDR-SP 500 TR (ETF:SPY): ETF Research Reports
     
    PWRSH-DYN SEMI (ETF:PSI): ETF Research Reports
     
    ISHARS-NA TEC-S (ETF:IGV): ETF Research Reports
     
    FIRST N-100 TEC (NASDAQ: QTEC): ETF Research Reports
     
    FT-TECH ALPHA (ETF:FXL): ETF Research Reports
     
    FT-NDQ SEMICON (FTXL): ETF Research Reports
     
    NVIDIA Corporation (NASDAQ: NVDA): Free Stock Analysis Report
     
    Macy's Inc (NYSE: M): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research
     
    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

invest financial: Bayer Aktiengesellschaft (BAYZF)


Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    We believe that the pharmaceutical sector has received too much negative attention. Despite the risks, a few companies offer good entry opportunities. In our previous article, we recommended Akorn. Today, we have analyzed Teva. We believe that the company is in a position to thrive in the generic market, and that it is priced very attractively. Yet, we don’t like management’s aggressive M&A strategy. We don’t like very aggressive companies since large acquisitions rarely create value for the shareholders. Contributors argue that Teva has overpaid for Actavis (its latest and largest acquisition) by at least $14B. This does not surprise us since most M&A deals are too expensive. Previous corruption issues add further doubts. Unfortunately, there is no amount of profit that can convince us to invest in a company where we do not like the management. We have sold our positions in Bayer (OTCPK:BAYZF) for similar reasons. We like Bayer, but we have sold our shares because of the Bayer-Monsanto (NYSE:MON) acquisition.

  • [By SEEKINGALPHA.COM]

    Other R&D products in Regeneron’s pipeline that we are interested in

    Fasinumab: Antibody against nerve growth factor, being developed for pain treatment like osteoarthritis. It is partnered with Teva Pharmaceutical (NASDAQ:TEVA) (for osteoarthritis, in phase 3), and is also being developed for treatment of chronic back pain. It is licensed to Mitsubishi Tanabe for the Japan territory. REGN2222: For prevention of RSV virus infection in infants, competing with Synagis from AstraZeneca (NYSE:AZN). Nesvacumab: Angiopoetin 2 antibody, being tested in combination with Eylea (in phase 2, partnered with Bayer (OTCPK:BAYZF)). Rinucumab (anti-PDGF): Being tested in treatment of wet AMD in combination with Eylea. Phase 2 trial was not successful, but the treatment duration was less (only 12 weeks versus 24 weeks for rival Ophthotech (NASDAQ:OPHT)). 28-week and 52-week data will be released later. With Ophthotech’s phase 3 failure with Fovista, we are bullish on Rinucumab’s commercial potential in wet AMD. Immuno-oncology pipeline: Checkpoint inhibitors and novel CAR-T; still in early stage.


    Click to enlarge

  • [By SEEKINGALPHA.COM]

    And this is pretty important ground. Hepatocellular carcinoma can be managed with local therapy (surgery, embolization, etc.), but at its most advanced stages, the options quickly start to thin out. For a decade, the only option in systemic therapy was Bayer’s (OTCPK:BAYZF) sorafenib. Recently, the effective systemic treatment armamentarium was doubled with the approval of regorafenib for second-line therapy.

Leave a Reply

Your email address will not be published.